NCT01413022View on ClinicalTrials.gov

FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

September 30, 2016

Conditions

Pancreatic Neoplasms

Interventions

DRUG

Oxaliplatin

DRUG

Irinotecan

DRUG

Leucovorin

DRUG

Fluorouracil

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

flow cytometry

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

OTHER

pharmacological study

Correlative studies

DRUG

PF-04136309

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT01413022 - FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter